175 related articles for article (PubMed ID: 33160278)
41. A novel postoperative inflammatory score predicts postoperative pancreatic fistula after pancreatic resection.
Fujiwara Y; Misawa T; Shiba H; Shirai Y; Iwase R; Haruki K; Furukawa K; Futagawa Y; Yanaga K
Anticancer Res; 2013 Nov; 33(11):5005-10. PubMed ID: 24222143
[TBL] [Abstract][Full Text] [Related]
42. Central pancreatectomy with external drainage of monolayer pancreaticojejunostomy for prevention of postoperative pancreatic fistula: A retrospective cohort study.
Yang F; Jin C; Di Y; He H; Hao S; Yao L; Li J; Fu D
Int J Surg; 2018 Mar; 51():104-108. PubMed ID: 29367037
[TBL] [Abstract][Full Text] [Related]
43. Preoperative CT anthropometric measurements and pancreatic pathology increase risk for postoperative pancreatic fistula in patients following pancreaticoduodenectomy.
Roh YH; Kang BK; Song SY; Lee CM; Jung YK; Kim M
PLoS One; 2020; 15(12):e0243515. PubMed ID: 33270774
[TBL] [Abstract][Full Text] [Related]
44. Risk Factors for Clinically Relevant Postoperative Pancreatic Fistula (CR-POPF) after Distal Pancreatectomy: A Single Center Retrospective Study.
Wang GQ; Yadav DK; Jiang W; Hua YF; Lu C
Can J Gastroenterol Hepatol; 2021; 2021():8874504. PubMed ID: 33542910
[TBL] [Abstract][Full Text] [Related]
45. Outcome of combined pancreatic and biliary fistulas after pancreatoduodenectomy.
Aghalarov I; Beyer E; Niescery J; Belyaev O; Uhl W; Herzog T
HPB (Oxford); 2023 Jun; 25(6):667-673. PubMed ID: 36842945
[TBL] [Abstract][Full Text] [Related]
46. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
[TBL] [Abstract][Full Text] [Related]
47. [The Efficacy of Neoadjuvant Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer].
Sano T; Takano K; Chiba N; Tomita K; Ozawa Y; Hikita K; Shimazu M; Kawachi S
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1488-90. PubMed ID: 26805072
[TBL] [Abstract][Full Text] [Related]
48. [Neoadjuvant Chemotherapy Using S-1 for Pancreatic Cancer - Mid-Term Results].
Homma Y; Honda G; Sakamoto K; Kurata M; Honjo M; Hirata Y; Shinya S
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1166-1170. PubMed ID: 27760934
[TBL] [Abstract][Full Text] [Related]
49. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer.
Kim MS; Lim JS; Hyung WJ; Lee YC; Rha SY; Keum KC; Koom WS
World J Gastroenterol; 2015 Mar; 21(9):2711-8. PubMed ID: 25759540
[TBL] [Abstract][Full Text] [Related]
50. Association between the Preoperative
Funamizu N; Sogabe K; Shine M; Honjo M; Sakamoto A; Nishi Y; Matsui T; Uraoka M; Nagaoka T; Iwata M; Ito C; Tamura K; Sakamoto K; Ogawa K; Takada Y
Nutrients; 2022 Dec; 14(24):. PubMed ID: 36558435
[TBL] [Abstract][Full Text] [Related]
51. Association between intraoperative and postoperative epidural or intravenous patient-controlled analgesia and pancreatic fistula after distal pancreatectomy.
Igarashi T; Harimoto N; Matsui Y; Muranushi R; Yamanaka T; Hagiwara K; Hoshino K; Ishii N; Tsukagoshi M; Watanabe A; Kubo N; Araki K; Saito S; Shirabe K
Surg Today; 2021 Feb; 51(2):276-284. PubMed ID: 32734348
[TBL] [Abstract][Full Text] [Related]
52. Pancreatic Fat and Body Composition Measurements by Computed Tomography are Associated with Pancreatic Fistula After Pancreatectomy.
Tanaka K; Yamada S; Sonohara F; Takami H; Hayashi M; Kanda M; Kobayashi D; Tanaka C; Nakayama G; Koike M; Fujiwara M; Kodera Y
Ann Surg Oncol; 2021 Jan; 28(1):530-538. PubMed ID: 32436185
[TBL] [Abstract][Full Text] [Related]
53. Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Propensity-Matched Analysis of Postoperative Complications Using ACS-NSQIP.
Krell RW; McNeil LR; Yanala UR; Are C; Reames BN
Ann Surg Oncol; 2021 Jul; 28(7):3810-3822. PubMed ID: 33386542
[TBL] [Abstract][Full Text] [Related]
54. Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer.
Sho M; Akahori T; Tanaka T; Kinoshita S; Nagai M; Nishiwada S; Tamamoto T; Nishiofuku H; Ohbayashi C; Hasegawa M; Kichikawa K; Nakajima Y
Langenbecks Arch Surg; 2015 May; 400(4):477-85. PubMed ID: 25929828
[TBL] [Abstract][Full Text] [Related]
55. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
56. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
57. Tumor location, clinicopathological features, and perioperative and prognostic outcomes in patients who underwent pancreatic resection following neoadjuvant chemoradiotherapy for resectable pancreatic cancer: A retrospective study.
Suto H; Matsukawa H; Fuke T; Nagao M; Ando Y; Oshima M; Yamana H; Kamada H; Kobara H; Okuyama H; Kumamoto K; Okano K
Pancreatology; 2024 May; 24(3):431-436. PubMed ID: 38383175
[TBL] [Abstract][Full Text] [Related]
58. Critical appraisal of 232 consecutive distal pancreatectomies with emphasis on risk factors, outcome, and management of the postoperative pancreatic fistula: a 21-year experience at a single institution.
Goh BK; Tan YM; Chung YF; Cheow PC; Ong HS; Chan WH; Chow PK; Soo KC; Wong WK; Ooi LL
Arch Surg; 2008 Oct; 143(10):956-65. PubMed ID: 18936374
[TBL] [Abstract][Full Text] [Related]
59. Risk of pancreatic fistula after enucleation of pancreatic tumours.
Strobel O; Cherrez A; Hinz U; Mayer P; Kaiser J; Fritz S; Schneider L; Klauss M; Büchler MW; Hackert T
Br J Surg; 2015 Sep; 102(10):1258-66. PubMed ID: 26109380
[TBL] [Abstract][Full Text] [Related]
60. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer.
Sho M; Akahori T; Tanaka T; Kinoshita S; Tamamoto T; Nomi T; Yamato I; Hokuto D; Yasuda S; Kawaguchi C; Nishiofuku H; Marugami N; Enomonoto Y; Kasai T; Hasegawa M; Kichikawa K; Nakajima Y
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):197-205. PubMed ID: 22766692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
